EUVIMEDEUVIMED entdecken
Crossref

Exploring key considerations for subcutaneous anticancer therapies

Tonya Baur

NCODA Oncology and Hematology Meeting Abstracts · 28.10.2026 · 2 (2)

DOI: 10.67209/park3649 ↗

Kurz gefasst

Fachartikel in der Zeitschrift NCODA Oncology and Hematology Meeting Abstracts, online erschienen am 28.10.2026. Verfasst von Tonya Baur. Die Arbeit nennt 9 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The continuous climb in the number of available anticancer therapies offers a captivating alternative to traditional intravenous (IV) therapies. The incorporation of hyaluronidase has led to the rise in the development of therapies given subcutaneously. A review of the literature included 169 publications and found that when comparing subcutaneous (SC) versus IV administration, studies concluded similar efficacy and decreased infusion chair times. Studies also concluded that SC formulations saved time and in turn improved patient, caregiver, and nursing staff quality of life.

Objectives

List at least three advantages for patients and the practice of transitioning to SC anticancer therapies. Identify at least two challenges of transitioning to subcutaneous anticancer therapies. Discuss why hyaluronidase is used in some anticancer subcutaneous formulations. Describe some proper body mechanics and/or different ways to administer subcutaneous anticancer therapies to prevent nursing injuries. Discuss the appropriate subcutaneous anticancer administration site and needle angles that should be utilized when providing these medications.

Purpose

The purpose of this project is to bring awareness of SC anticancer formulations available and the pros and cons when switching to SC formulations versus traditional IV formulations.

Methods

A review of the literature was performed including journal articles, podcasts, and online resources. The primary themes were reviewed and pulled from the literature.

Results

The key findings from the review included decreased chair time, increased treatment/patient satisfaction, and improved caregiver productivity. However, there was a higher incidence of injection-site reactions compared to IV formulations. Due to the high volume of medication that is administered subcutaneously, hyaluronidase is often used in these formulations to increase absorption and help with injection tolerance. The use of SC formulations was also shown to have fewer or no infusion reactions as compared to the IV preparations. Additionally, decreased infections were noted due to not using central lines for administration. Using proper body mechanics during administration and/or administration sets tends to prevent caregiver injuries. The main negative themes of these SC formulations consisted of injection-site reactions and patients who have needle phobia.

Conclusion

In conclusion, the transition of anticancer medication from IV to SC administration is growing drastically with new formulations being approved consistently. It is important to use correct body mechanics during administration. Nurses should prepare themselves with the knowledge of how and at what site these medications should be administered and how to monitor for injection-site reactions. It is also important to educate your nursing staff on the appropriate needle size, site, and administration time of each anticancer SC medication that they are providing and to follow the medication manufacturing guidelines for preparation and administration. Funding: Not applicable.

Zitieren

APA

Baur, T. (2026). Exploring key considerations for subcutaneous anticancer therapies. NCODA Oncology and Hematology Meeting Abstracts, 2(2). https://doi.org/10.67209/park3649

Vancouver

Baur T. Exploring key considerations for subcutaneous anticancer therapies. NCODA Oncology and Hematology Meeting Abstracts. 2026;2(2). doi:10.67209/park3649

BibTeX
@article{Baur2026,
  author = {Baur, Tonya},
  title = {Exploring key considerations for subcutaneous anticancer therapies},
  journal = {NCODA Oncology and Hematology Meeting Abstracts},
  year = {2026},
  volume = {2},
  number = {2},
  doi = {10.67209/park3649}
}
Kostenlos starten →